After last year's public rejection, BrainStorm to give ALS cell therapy another shot despite still flunking a re-analyzed PhIII

After a rare public rejection from the FDA last year, BrainStorm Cell Therapeutics is headed back to the regulator with what it claims is a …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Af­ter last year's pub­lic re­jec­tion, Brain­Storm to give ALS cell ther­a­py an­oth­er shot de­spite still flunk­ing a re-an­a­lyzed PhI­II